Aventis Ketek
Executive Summary
FDA requests additional data from Aventis on Ketek (telithromycin) in "approvable" letter for treatment of community acquired pneumonia, bacterial exacerbations of chronic bronchitis and acute bacterial sinusitis. Tonsillitis/pharyngitis indication is "not approvable," letter adds